top of page

Positron Corporation Announces First Step in Validation of its New PET-CT Device

Updated: Dec 21, 2022

Niagara Falls, NY – August 16, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce that its first PET-CT system has been purchased and is in transit from its partner Neusoft Medical Systems. Positron’s system named “Affinity PET-CT" is en route from China to its validation partner in the United States, which is set to arrive in late September 2022.

This important milestone marks the beginning of the most critical step in the launch of Positron’s Affinity PET-CT nuclear imaging device. The Company will soon announce the hospital, physician, and other key parties performing and participating in the Company’s validation procedure, with performance results to follow.

The Company also expects to submit the systems 510K application to the FDA in the coming weeks.

Adel Abdullah, President of Positron, stated: “The validation and performance review of Positron’s new Affinity PET-CT is a key step for the introduction of the system to both cardiac and oncology imaging and diagnostics. I’m proud of our team, especially the many leading nuclear imaging industry parties that have all agreed to assist and perform the comprehensive studies necessary to showcase our state-of-the-art PET-CT system. All are excited to begin in September with an expected completion date by November 2022.”

bottom of page